Remarkable to see that our discoveries over 15 years ago would enable such tremendous advances for sickle cell disease and thalassemia!!! Incredible to think that the final sentence of our 2008 paper would be prophetic (science.org/doi/10.1126/sc…)... statnews.com/2023/11/16/u-k…

Two exciting manuscripts from @Michel_Sadelain and Amigorena labs established that SUV39H1 disruption enhance CAR T cells functional persistence in liquid and solid tumors independently of the CAR design or target! doi.org/10.1158/2159-8… doi.org/10.1158/2159-8…

Israeli Welfare Ministry confirmed that these are instructions for IDF personnel who will be escorting child hostages from Gaza to Israel: 1. Try to have 1 soldier escort each child or family unit 2. The soldier should introduce himself: “Hi, I’m (name). I’m a soldier in the

Noa is featured in this month's National Wildlife! National Wildlife Federation Fridays For Future NYC nwf.org/Home/Magazines…

A major milestone today as FDA accepts our application for review. Proud to be part of the team developing a new medicine for patients with multiple myeloma. investor.regeneron.com/news-releases/…

FDA grants priority review for our new #myeloma medicine linvoseltamab. One step closer to bringing this medicine to patients. Proud to be on this team! investor.regeneron.com/news-releases/…

hey Alie Ward, Whale Scientist was my anatomy instructor and I learned so much listening to your interview with her! What a delight!!

Hopefully Joe Biden and The White House are listening commondreams.org/opinion/biden-…

The ODAC on 3/15/24 on cilta-cel and ide-cel was like a plenary or late breaking abstracts session at ASH along with elements of America’s Got Talent. Lots of data being presented, discussion and analysis, and voting too!

Sundar Jagannath at ⁦AACR⁩ presenting the updated data on Linvoseltamab. Fingers crossed for FDA approval later this year. ⁦The Tisch Cancer Institute⁩ ⁦Mount Sinai Health System⁩ #mmsm

via @NYTOpinion ⁦Bill Maher⁩ nytimes.com/2024/04/08/opi…

Sadly, NIH funding of thyroid research has decreased dramatically in the last ten years, from about $50M to $30M/year. What is going on???? AACE American Thyroid Association Endocrine Society Endocrine News pubmed.ncbi.nlm.nih.gov/38661525/

Oh Spock! Even 23rd century hematology should have known the difference between hemoglobin and O2 sat. #startrek

CONGRESS #EHA2024 | @Slentzsch Columbia University Herbert Irving Comprehensive Cancer Center discusses results from the phase I/II LINKER-MM1 trial of linvoseltamab monotherapy in patients with R/R MM. Linvoseltamab demonstrated high efficacy and a tolerable safety profile in patients with R/R MM. #mmsm #myeloma

Greatly encouraging data -- linvoseltamab also cutting down on required hospitalization time for monitoring compared to tec! (And that's my mentor on stage!!) Suzanne Lentzsch, MD, PhD

#Myeloma Paper of the Day: Linvoseltamab BCMA TCE shows ORR 71% (50% ≥CR) in relapsed/refractory myeloma, with impressive median DOR of 29.4 months, while common AEs included CRS (0.9% Grade 3), neutropenia, anemia, infections, and ICANS (7.7%): pubmed.ncbi.nlm.nih.gov/38879802/.

Excited for this drug. The first patient I enrolled on this trial Sylvester Comprehensive Cancer Center was planned for hospice… she is alive and well 5+years later! ascopubs.org/doi/10.1200/JC…

Honored to by co-lead author with Naresh Bumma on this amazing paper: #msmm Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma | Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

Great data #mmsm

Customer service matters. Rivian I can't get any information about an order, and this is now costing me time, money, and making it difficult to make plans with family. RJ Scaringe maybe someone can reach out?